Lilly’s gene editor cuts LDL cholesterol up to 62% in one dose

Eli Lilly ↘1.21% said its base-editing therapy VERVE-102 reduced LDL cholesterol by up to 62% and PCSK9 protein by up to 88% in 35 participants.moomoo
The one-time infusion uses CRISPR-based technology to permanently disable the PCSK9 gene in the liver, potentially replacing lifelong injectable cholesterol drugs.moomoo
The FDA has granted Fast Track designation, and Lilly says it plans to begin Phase 2 enrollment by the end of 2026.moomoo

Lilly’s VERVE-102 Gene Editor Cuts LDL Cholesterol by Up to 62% in Phase 1b Trial

Eli Lilly announced on Sunday that its one-time gene editing therapy VERVE-102 achieved dose-dependent reductions in LDL cholesterol of up to 62% in an interim analysis of the Phase 1b Heart-2 trial, marking a milestone for the nascent field of cardiovascular gene editing.moomoo

The results, drawn from 35 participants at high risk for cardiovascular disease, showed that a single intravenous infusion of VERVE-102 reduced PCSK9 protein levels by 51% to 88% across dose cohorts ranging from 0.3 mg/kg to 1.0 mg/kg. Corresponding LDL-C reductions ranged from 9% at the lowest dose to 62% at the highest, with effects sustained for up to 18 months.moomoo

How It Works

VERVE-102 uses base editing technology — a refined form of CRISPR — to make a single DNA letter change in the PCSK9 gene within liver cells, permanently shutting off production of a protein that drives up cholesterol levels. Unlike injectable PCSK9 inhibitors such as Amgen’s Repatha, which patients must take every two to four weeks, VERVE-102 is designed as a single-course treatment.vervetx

The therapy was well tolerated across all dose levels, with no treatment-related serious adverse events or dose-limiting toxicities reported. Side effects were limited to low-grade infusion-related reactions and fatigue, and all participants received the full planned dose without withdrawals.moomoo

Path Forward

The U.S. Food and Drug Administration has granted Fast Track designation for VERVE-102, and Lilly said it expects to begin enrolling patients in a Phase 2 study by the end of 2026. The trial is recruiting at sites across the United States, United Kingdom, Canada, Israel, Australia, and New Zealand.clinicaltrials

Lilly acquired Verve Therapeutics for up to $1.3 billion in a deal that closed in July 2025, gaining access to the company’s base editing platform. The earlier April 2025 readout from Heart-2, which included 14 participants and showed a mean LDL-C reduction of 53% at the 0.6 mg/kg dose, had sent Verve’s shares up more than 26%. The latest data, with higher doses and longer follow-up, strengthen the case that a one-time gene edit could rival or exceed the cholesterol-lowering effect of existing injectable therapies that require lifelong dosing.crisprmedicinenews